Virax Biolabs Group (Virax Biolabs Group) Change In Receivables : $-0.18 Mil (TTM As of Sep. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Virax Biolabs Group Change In Receivables?

Virax Biolabs Group's change in receivables for the quarter that ended in Sep. 2023 was $-0.18 Mil. It means Virax Biolabs Group's Accounts Receivable increased by $0.18 Mil from Mar. 2023 to Sep. 2023 .

Virax Biolabs Group's change in receivables for the fiscal year that ended in Mar. 2023 was $0.00 Mil. It means Virax Biolabs Group's Accounts Receivable stayed the same from Mar. 2022 to Mar. 2023 .

Virax Biolabs Group's Accounts Receivable for the quarter that ended in Sep. 2023 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Virax Biolabs Group's Days Sales Outstanding for the six months ended in Sep. 2023 was 0.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Virax Biolabs Group's liquidation value for the six months ended in Sep. 2023 was $4.20 Mil.

Virax Biolabs Group Change In Receivables Historical Data

The historical data trend for Virax Biolabs Group's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virax Biolabs Group Change In Receivables Chart

Virax Biolabs Group Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Change In Receivables

Virax Biolabs Group Semi-Annual Data
	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Change In Receivables	Get a 7-Day Free Trial			-	-	-	-	-0.18

Virax Biolabs Group Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.18 Mil.

Virax Biolabs Group (NAS:VRAX) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Virax Biolabs Group's Days Sales Outstanding for the quarter that ended in Sep. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0.077	*	91
=	0.00

2. In Ben Graham's calculation of liquidation value, Virax Biolabs Group's accounts receivable are only considered to be worth 75% of book value:

Virax Biolabs Group's liquidation value for the quarter that ended in Sep. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	5.108	-	0.919	+	0.75 * 0	+	0.5 * 0.025
=	4.20

Virax Biolabs Group Change In Receivables Related Terms

Thank you for viewing the detailed overview of Virax Biolabs Group's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Virax Biolabs Group (Virax Biolabs Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

20 North Audley Street, London, GBR, W1K 6LX

Website

https://www.viraxbiolabs.com

Virax Biolabs Group Ltd is a innovative biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.